DOUGLAS E WILLIAMS
CIK 1184847 · EVP & President, R&D · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.70M
Companies
11
Total Filings
77
Lifetime Open-Market Net
-$3.68M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Climb Bio, Inc. (ELYM) Delisted | Director | — | $5.11 | — | $0 | 4 | 2026-06-08 |
| CAMP | Director | — | $4.19 | — | $0 | 1 | 2025-03-19 |
| SANA | EVP & President, R&D | — | $2.68 | — | $0 | 3 | 2024-03-08 |
| Codiak BioSciences, Inc. (CDAK) Delisted | President & CEO | 7,655 | $0.06 | $436 | -$30.7K | 8 | 2023-03-30 |
| OVID | Director | 5,000 | $2.30 | $11.5K | $32.4K | 7 | 2021-05-18 |
| IRWD | Director | 87,800 | $3.65 | $320.5K | $0 | 5 | 2019-04-03 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | — | $8.16 | — | $0 | 4 | 2016-06-03 |
| BIIB | EVP Research & Development | 11,817 | $200.05 | $2.36M | -$3.73M | 16 | 2015-06-22 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | Director | 19,961 | — | — | $0 | 8 | 2013-06-14 |
| ZYMOGENETICS INC (ZGEN) Delisted | Chief Executive Officer | 0 | $12.01 | $0 | $47.0K | 12 | 2010-10-12 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Director | 4,500 | — | — | $4.7K | 4 | 2008-05-30 |
Recent Filings · Page 3 of 8
77 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-06-10 | OVID | Grant (A) | — | $0 | EDGAR |
| 2019-04-03 | IRWD | Disp (D) | −4,056 | $0 | EDGAR |
| 2018-08-16 | OVID | Buy (P) | +5,000 | $32.4K | EDGAR |
| 2018-06-08 | OVID | Grant (A) | — | $0 | EDGAR |
| 2018-06-04 | IRWD | Grant (A) | +16,223 | $0 | EDGAR |
| 2017-06-02 | IRWD | Grant (A) | +15,625 | $0 | EDGAR |
| 2016-06-03 | IRWD | Grant (A) | +23,674 | $0 | EDGAR |
| 2016-06-03 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-26 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-22 | BIIB | Sell (S) | −3,841 | -$1.57M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.